TNFSF11 and Fabry disease: Denosumab, a human monoclonal antibody targeting the receptor activator of nuclear kappa factor B ligand (RANKL), has recently emerged as a potential treatment for adults and children with FD of the bone, although it is not currently FDA approved for this condition.